Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer

StatusRecruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 9 months later Mar 1, 2028 → Dec 31, 2028
See other at-risk trials from Acerand Therapeutics (Hong Kong) Limited

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: details revised at 2 of 3 entries
    • Trial sites expanded: 9 → 13 locations
    • Eligibility criteria expanded, about 20 words
    • Secondary endpoints: details revised at 1 of 8 entries
  2. Primary completion pushed from Mar 1, 2028 to Dec 31, 2028
    • Enrollment increased: 67 → 88 participants
    • Study completion pushed from Aug 1, 2028 to Dec 31, 2028
    • Study sites: 8 to 9
    v8
  3. Site details revised at 1 of 8 sitesv7
  4. Site details revised at 2 of 8 sitesv6
  5. Site details revised at 3 of 8 sitesv5
Show 3 earlier versionsHide 3 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 6 to 8
    • Start date changed from estimate of May 1, 2025 to May 12, 2025
    v4
  2. Start date: Apr 1, 2025 to May 1, 2025
    • Study sites: 2 to 6
    v3
  3. Study description shortened, about 32 wordsv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an open label, phase I, multi-center study aiming to assess the safety and tolerability in patients with metastatic castration resistant prostate cancer (mCRPC).
Trial Details
NCT Number NCT06801236
Lead Sponsor Acerand Therapeutics (Hong Kong) Limited
Conditions
(from sponsor)		 Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer)
Related terms Adenocarcinoma, Prostatic Neoplasms
Enrollment 88 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov